Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of an Ethanol/Sodium Citrate Locking Solution: A Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with Stage V chronic kidney disease preparing to start hemodialysis~* Exchange of an existing catheter to a cuffed, tunneled catheter OR planned vascular access with a cuffed, tunneled catheter~* CVC used for hemodialysis made of alcohol-resistant polymers ie. carbothane~Exclusion Criteria:~* Patients receiving catheters not made of alcohol resistant polymers~* Critically ill patients in ICU setting~* Patients with acute renal failure, who will likely not require prolonged vascular access ( ie. \> months)~* Patients with maturing fistulas/graft creation within 2 months~* Patients with planned antibiotic treatment courses lasting longer than 4 weeks from the date of new catheter insertion~* Patients receiving a new cuffed, tunneled catheter over a guide wire, if a fibrin sheath angioplasty was not performed after removing the previous dysfunctional catheter

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 30 % ethanol/ 4 % sodium citrate group (Type: EXPERIMENTAL): For patients randomized to the 30% ethanol /4 % sodium citrate group, the lock solution will be provided in pre-filled syringes for single use only. After each dialysis session, the locking solution will be instilled into both catheter lumens, the lumens clamped and caps tightly secured to the hubs. Any remaining 30% ethanol/4% sodium citrate solution in each syringe will be discarded. The locking solution will be withdrawn from the catheter lumens before the next dialysis session.
- Heparin 1000 U/ml (Type: EXPERIMENTAL): For patients randomized to the heparin group, the heparin will be provided in 10 ml glass vials. Two, 3 ml syringes will be used to draw up the required volume of heparin to fill each lumen. A separate syringe will be used to fill each catheter lumen. The necessary volume should match the lumen volume with no overfill. The locking solution will be instilled into both catheter lumens, the lumens clamped and caps tightly secured to the hubs. The locking solution will be withdrawn from the catheter lumens before the next dialysis session.

Based on this trial design, predict the completion outcome and termination type (if applicable).